Cassava Sciences announced a 33% workforce reduction, cost-cutting measures, and anticipated topline data release from its Phase 3 REFOCUS-ALZ...

Asher Biotherapeutics and AstraZeneca have partnered to evaluate etakafusp alfa (AB248), Asher Bio’s CD8+ T cell-targeted IL-2 immunotherapy, in...

Micron Biomedical received a $7.5 million grant from the Bill & Melinda Gates Foundation, bringing total funding from the...

Solid Biosciences has received FDA clearance for its Investigational New Drug (IND) application for SGT-212, a gene therapy designed...

Sana Biotechnology announced positive initial results from a first-in-human study involving a patient with type 1 diabetes. The study,...

A 36-month study using data from the American Academy of Ophthalmology IRIS® Registry demonstrated that Sight Sciences’ OMNI® Surgical...

Immix Biopharma has completed the safety run-in portion of its U.S. Phase 1b NEXICART-2 study for NXC-201, a CAR-T...

Cyclarity Therapeutics has received regulatory approval to commence its first-in-human clinical trial for UDP-003 at CMAX in Australia, partnered...

Biomea Fusion announced positive preclinical data for icovamenib combined with semaglutide, a GLP-1 receptor agonist, in treating type 2...

Grove AI, a clinical trial management company, secured $4.9 million in seed funding led by A•, with participation from...